<DOC>
	<DOCNO>NCT02807844</DOCNO>
	<brief_summary>The purpose study MCS110 PDR001 characterize safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , antitumor activity combination MCS110 PDR001 adult patient solid tumor .</brief_summary>
	<brief_title>Phase Ib/II Study MCS110 Combination With PDR001 Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Signed informed consent prior procedure Patients advance melanoma , endometrial carcinoma , pancreatic TNBC , measurable nonmeasurable disease progress despite standard therapy intolerant standard therapy , standard therapy exists . Patient range laboratory value define : Creatinine clearance &lt; 40 mL/min Total bilirubin &gt; 1.5 x ULN Absolute neutrophil count &lt; 1.0 x 109/L Hemoglobin ( Hgb ) &lt; 9 g/dL Impaired cardiac function clinically significant cardiac disease Active autoimmune disease Malignant disease , treat study . Presence â‰¥ CTCAE Grade 2 toxicity due prior cancer therapy . Pregnant lactating woman Other protocoldefined inclusion/exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Triple negative breast cancer</keyword>
	<keyword>Pancreatic carcinoma</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Endometrial Carcinoma</keyword>
	<keyword>Immuno oncology</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>PDR001</keyword>
	<keyword>MCS110</keyword>
</DOC>